Benralizumab Normalizes Sputum Eosinophilia in Severe Asthma Uncontrolled by Anti-IL-5 Antibodies: A Single-Blind, Placebo-controlled Clinical Trial

Am J Respir Crit Care Med. 2023 Dec 15;208(12):1330-1335. doi: 10.1164/rccm.202308-1413LE.
No abstract available

Publication types

  • Randomized Controlled Trial
  • Letter

MeSH terms

  • Anti-Asthmatic Agents* / therapeutic use
  • Antibodies / therapeutic use
  • Asthma* / complications
  • Asthma* / drug therapy
  • Double-Blind Method
  • Eosinophilia* / drug therapy
  • Eosinophils
  • Humans
  • Interleukin-5 / immunology
  • Interleukin-5 / therapeutic use
  • Pulmonary Eosinophilia* / drug therapy
  • Single-Blind Method
  • Sputum / drug effects
  • Sputum / metabolism

Substances

  • Anti-Asthmatic Agents
  • benralizumab
  • Interleukin-5
  • Antibodies